Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454580 | 0.84 | TSHR (0.55) | PDE4DNPSR1BLMTSHR | |
| SCHEMBL21729817 | 0.82 | TNF (0.47) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23746593 | 0.76 | TNF (0.45) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17875268 | 0.76 | ACHE (0.61) | TSHRMAPTRAB9A | |
| SCHEMBL17754960 | 0.76 | RAB9A (0.51) | NPSR1MAPTRAB9A | |
| SCHEMBL14349888 | 0.76 | ABCB11 (0.67) | TSHRMAPT | |
| SCHEMBL5487061 | 0.75 | TNF (0.39) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5438334 | 0.75 | TNF (0.44) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12268259 | 0.74 | ALDH1A1 (0.51) | TNFTSHRMAPTRAB9A | |
| SCHEMBL27462122 | 0.74 | ALDH1A1 (0.51) | TNFTSHRMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1690538-A1 | ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2006-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | NR1H3, NR1H2, RXRA | TNF 4697/4885PDE4A 1987/4885PDE4B 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.